Summary.-The presence of a tumour-associated immune response in 37 patients with ovarian cancer as assessed by blastogenesis (lymphocyte transformation) evoked by ovarian cancer cell extracts, has been correlated with survival following the test. The difference in these responses is unlikely to be accounted for on the basis of general impairment of cell-mediated immuno-competence.
Summary.-The presence of a tumour-associated immune response in 37 patients with ovarian cancer as assessed by blastogenesis (lymphocyte transformation) evoked by ovarian cancer cell extracts, has been correlated with survival following the test. The difference in these responses is unlikely to be accounted for on the basis of general impairment of cell-mediated immuno-competence.
Serum carcinoembryonic antigen (CEA) was also determined in 27 ovarian cancer patients to assess its prognostic significance. Raised CEA levels and absence of blastogenic response to tumour cell extract during relapse are associated with a worse prognosis but neither of these parameters are significant in remission.
Possible applications of these findings to the clinical management of ovarian cancer patients are discussed.
Serum alpha feto-protein levels measured by radioimmunoassay were not found to be raised in any of the 32 ovarian cancer patients in whom it was measured.
ANERGY to secondary recall antigens in cancer patients has been associated with a bad prognosis. Patients with adult leukaemia who are anergic to secondary recall antigens in vivo before induction of remission are reported to have a worse prognosis than those who respond to at least one out of 5 recall antigens (Hersh et al., 1974) . Eilber and Morton (1970) also showed that 930 of patients with solid tumours who did not develop primary skin responses to dinitrochlorobenzene preoperatively were either inoperable or developed early tumour recurrence.
We have recently reported that ovarian cancer patients show in vitro evidence of sensitization to determinants present in ovarian cancer cell extracts, and that this occurs more often in remission than during relapse (Levin et al., 1975a) . We are now able to correlate these blastogenic responses to ovarian cancer cell extract (OCE) with subsequent short term survival. Raised levels of CEA have been found in ovarian cancer patients (Di Saia et al., 1975; Barrelet and Mach, 1975; van Nagell et at., 1975; Seppala, Pihko and Rouslahti, 1975) . Patients in relapse have been shown to have generally higher levels. CEA was measured in most of the patients in this series so that evidence of the relationship of these isolated levels to survival is likewise available. The patients' serum was also screened for raised levels of alpha feto-protein (AFP).
METHOD AND MATERIALS
The ovarian cancer cell extract (OCE) from common epithelial tumours was prepared, and lymphocyte cultures were set up, as previously described (Levin et al., 1975a) ; and 106 mononuclear cells, mnostly lymphocytes, were stimulated with 100 jtg of OCE.
After incubating at 37 C in 50o C02, for 5 days the extent of transformation wAas assessed by subtracting the radioactive incorporation of 125IUDR (5-iodo-2-deoxyuridine) by unchallenged lymphocytes from that of challenged lymphocytes (et/min difference). From previous data (Levin et al., 1975a) patients with a ct/min difference greater than 500 (stimulation index, S.I. > 1-2) were regarded as having a blastogenic response to OCE, since none of the 18 controls had a blastogenic response greater than this.
CEA wias measured by a double antibody radioimmunoassay method of Egan et al. (1972) and modified by using a single label (1251 -CEA) as described by Laurence et al. (1972) . AFP was measured by a radioimmunoassay method as described by Leek and Chard (1974) ; highly purified AFP was used in this assay and polyethylene glycol used for separation of bound and free antigen.
The tumour histology was reviewed in the Williamson Laboratory as part of an on-going research programme (Curling and Hudson, 1975) .
Patients
Definitive staging of new cases according to the criteria of the International Federation of Gynaecology and Obstetrics (FIGO) was made at operation (Table I) . Nearly all patients wiere treated with chemotherapy involving the use of at least one alkylating agent. Two patients received experimental immunotherapy, details of w%Nhich are reported elsewhere (Levin et al., 1974) .
Patients in remission had no evidence of persistent or active disease following surgery with or without adjuvant therapy and had had no treatment for 30 days prior to testing.
Patients referred to as being in relapse had active disease spread beyond the ovary.
The blastogenic reponse to tumour extract was assessed in 21 remission patients, CEA assayed in 20 remission patients and AFP in 13 remission patients.
The testing and survival time in patients with recurrent disease refers only to the period under observation. Blastogenic responses to tumour extract were assessed in 16 relapse patients, CEA assayed in 23 relapse patients and AFP in 19 relapse patients.
Patients in i-emission and relapse who died of causes unrelated to their tumour wNere not included in this series.
The 18 controls in whom CEA was measured, were all healthy non-pregnant females, matched for age with the ovarian cancer patients and most were awaitiing elective surgery for prolapse repair.
RESULTS

Blastogenic assay
Individual survival times for relapse and remission patients are shown in Fig. 1 Conversely all 8 relapse patients (100%) who demonstrated a blastogenic response to OCE were alive after 6 months; two have subsequently relapsed after 12 and 15 months, 3 are well but with quiescent disease and 3 are disease free. The median survival for this group is l2-5 months (range 7-18 months). This difference is significant at the 300 level (Fisher's exact probability test).
The median age of relapse responders was 60 years (range 51-68) and the median age of relapse non-responders was 59 years (range 38-72).
Data relating to tumour staging and histological types in relapse responders and non-responders are presented in Table I Alpha feto-protein acssay
The upper limit in normal nonpregnant females, using this assay is 25 ng/ml (Rouslahti and Seppala, 1972) .
None of the 32 ovarian cancer patients in whom AFP was measured had raised levels; the median level was 9 5 ng/ml and the range was 0 8-19 ng/ml. DISCUISSION An impaired in vitro tumour-associated cell-mediated immmune response during relapse appears to be associated with a poor prognosis, most of the patients dying within 6 months of the test being performed. Of interest is the fact that the longest surviving patient in this group was on immunotherapy and she survived for 12 months. The other patient on immunotherapy, who has been followed up for only 8 months so far, is alive with quiescent disease.
All 8 relapse patients who demonstrated a blastogenic reponse to OCE are alive 6 months after the test.
There is no evidence that the difference in results between relapse responders and non-responders could be accounted for on the basis of age distribution in these groups or on the basis of histological types of tumour. While there is evidence for some correlation between tumour load and tumour-associated immune response this clearly will not account for the difference between the two groups.
In data not yet published we have found that while ovarian cancer patients do not have an impaired blastogenic response to PPD, responses to PHA are reduced in relapse patients. Both PHA and PPD induce predominantly T-cell blastogenesis (Kreeftenberg, Leerling and Loggen, 1975) , but the response to PPD probably follows more closely the mechanism of the response to tumour-associated antigen in this system, since PHA is a powerful mitogen which requires no presensitization to induce blastogenesis whereas PPD and (one would assume) The question whether the blastogenic assay might be assessing CEA has been considered; Lejtenyi, Freedman and Gold (1971) found that CEA was incapable of giving rise to blastogenesis. In one of our tumour extracts at a concentration of 2 mg/ml no evidence of CEA could be detected by radioimmunoassay.
Clinical implications Barrelet and Mach (1975) have shown that high CEA levels in ovarian cancer relapse patients will fall to normal levels with adequate treatment. We have now shown that it is possible to produce a tumour-associated cell-mediated immune response in ovarian cancer patients by inoculating them with ovarian cancer cells (Levin et al., 1975c) .
It remains to be seen whether special therapeutic attention to an identified group with elevated CEA and/or no evidence of a blastogenic response to tumour extract can improve the salvage rate, and indeed whether the addition of immunotherapy can help the latter group or whether its preferred role would be rather to boost the response of those patients still capable of mounting a tumour-associated cell-mediated immune response.
Cyonclussion
In vitro evidence of tumour-associated immunity, assessed by lymphocyte transformation appears to be an important parameter in assessing the prognosis of ovarian cancer patients in relapse but not for patients in remission from disease. 
